Masanobu Mitsuhashi,
Chief Executive Officer
It is absolutely fortunate for us to play an important role as a CRO in the clinical development industry where we are allowed to contribute to the patients suffering from diseases, disorders, and inconveniences as well as the societies and environments surrounding them.
Mediscience Planning Inc. has evolved in the circumstances with the change of the social milieux and innovation with the use of AI, big data, etc. in the drug discovery so we will retain our ability to meet the customers' requirements in a broader range along with our competing CROs.
MPI has aggregated a variety of services to make a multidisciplinary CRO so as to fulfill our customers' satisfaction and has improved our capabilities in clinical development as a company to fulfill our employees' satisfaction.
A variety of services to fulfill our customers' satisfaction as well as capability improvement to fulfill our employees' satisfaction are our challenges moving forward. MPI will earnestly work through the challenges as a critical part of our organization toward the sound contribution, the management principle of MPI.
We would highly appreciate your support to MPI moving forward.